CSL (ASX:CSL) shares rose nearly 1% in morning trade Monday after the biotechnology company secured marketing authorization from Health Canada for Andembry as a once-monthly treatment for hereditary angioedema attacks in adult and pediatric patients aged 12 years and older.
Andembry is designed to target activated FXII, a plasma protein that plays a key role in the attacks, according to the company's Friday, Aug. 8 release.
Hereditary angioedema is a rare and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of swelling in various parts of the body.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.